As the year comes to a close, it’s a good time to pause and look back on everything we’ve achieved together in 2025. It’s been another busy, rewarding year at MAC – full of progress, challenges and moments that reminded us why the work we do matters.
Over the past 12 months, our teams have continued to deliver high-quality clinical research, strengthen our capabilities, and work closely with Sponsors and partners to move important studies forward. And while no year is without its hurdles, we’re proud of what we’ve accomplished, and grateful to the people who made it possible!
Moving studies forward
Supporting the delivery of complex clinical trials remained at the heart of what we do in 2025.
Throughout the year, we supported a number of significant clinical programmes. One of the highlights was the successful completion of a pivotal hub-and-spoke model study, an important milestone that reflects how MAC continues to evolve in response to the needs of Sponsors and studies.
We are proud to have completed a Phase I clinical trial for KP405, a brain-penetrant GLP-1/GIP analogue designed to slow the progression of Parkinson’s Disease Dementia, delivered in collaboration with Kariya Pharmaceuticals.
We also successfully dosed 70 patients in a Phase II study for Social Anxiety Disorder, announced the clinical development of Mavatrep, and partnered with Initiator Pharma on a Phase IIa vulvodynia trial.
As the complexity of studies continues to increase, so too does the need for strong clinical oversight. In 2025, we launched a dedicated Medical Monitoring department, which has already received positive feedback from Sponsors for its role in supporting complex studies and maintaining participant safety.
Quality You Can Rely On
Behind every study is a strong foundation of quality and compliance. Throughout 2025, MAC maintained this focus, again retaining our MHRA Phase I accreditation, a status we have held continuously since 2016, alongside the successful hosting of a MHRA GCP inspection. This accreditation enables the delivery of First-in-Human and other early-phase studies and places MAC among a small number of UK sites approved to do so.
We also continue to hold ISO 17025 accreditation, achieved Cyber Essentials reaccreditation, and maintained our EcoVadis Bronze rating. These accreditations and assessments are an important reflection of the standards our teams work to every day.
The year also saw practical developments to support future growth, including an addition to our manufacturing licence to include “Specials”, improving flexibility for upcoming studies. Alongside this, we continued building our Pharmacovigilance function, with the department launching in Q4 2025 following a year of careful setup, recruitment, training and process development.
Sharing knowledge and starting conversations
In 2025, we placed greater emphasis on sharing insight and connecting with the wider clinical research community. We launched a new MAC email channel to keep Sponsors and partners up to date, and introduced MAC: Behind the Trials, a video podcast series designed to open up conversations around clinical research.
Across six episodes, we welcomed 12 expert guests from within MAC, reached viewers in 14 countries, and racked up more than 49,000 views – a clear sign there’s real appetite for open, honest conversations about the world of clinical research. We also hosted two webinars focused on EEG biomarkers and psychedelics and published four LinkedIn newsletter articles as part of MAC Clinical Research Insights.
These pieces received over 10,000 article views and explored topics ranging from the role of healthy volunteers to data integrity and Australia’s growing role in global clinical research.
Supporting causes that matter
Beyond clinical research, MAC colleagues once again came together to support a new Charity of the Year, Refuge, and raised over £3,000 during 2025. It’s lovely to see our teams putting their time and energy into causes that make a real difference.
Looking ahead
As we reflect on 2025, we’re proud of everything we’ve achieved but even more excited for what’s to come. None of this would be possible without the dedication of our teams, the trust of our Sponsors and partners, and the contribution of the participants who take part in our studies.
We can’t wait to build on this progress and continue to deliver clinical research that makes a meaningful difference. Here’s to a successful 2026!
You can find out more about MAC and get in touch with us here.
